Nobel Prize in Physiology or Medicine 2020: The Discovery of Hepatitis C Virus

This note covers the Nobel Prize in Physiology or Medicine 2020: who won it, how Hepatitis C virus was discovered through decades of patient studies, molecular cloning and chimpanzee experiments, how the discovery unfolded, why it matters for blood safety and antiviral cures, and quick facts for exams.

What was the Nobel Prize in Physiology or Medicine 2020 awarded for?

The citation reads: "for the discovery of Hepatitis C virus". In plain words, the three laureates together worked out, over several decades, that a large number of unexplained cases of blood-borne liver disease were caused by a single, previously unknown virus, and they proved this step by step: first by showing the disease existed and was infectious, then by isolating the virus's genetic material, and finally by showing that the virus on its own could cause the disease.

The prize's official name is the Nobel Prize in Physiology or Medicine. It recognises discoveries that have, in the words used by the Nobel Assembly, benefited humankind, and the 2020 award singled out work that made possible reliable blood tests and curative drugs for a disease that had silently damaged millions of livers worldwide.

Who are the laureates?

Harvey J. Alter

Harvey J. Alter was born on 12 September 1935 in New York, NY, USA. At the time of the award he was affiliated with the National Institutes of Health (NIH), Bethesda, MD, USA, and he received one third of the prize.

Studying patients who had received blood transfusions, Alter and his colleagues showed that a contagion distinct from the known hepatitis A and B viruses was also causing chronic hepatitis, and demonstrated that this unknown agent had the properties of a virus, transmissible even to chimpanzees.

Michael Houghton

Michael Houghton was born in 1949 in the United Kingdom. At the time of the award he was affiliated with the University of Alberta, Edmonton, Canada, and he received one third of the prize.

Working at the pharmaceutical firm Chiron, Houghton and his co-workers isolated the genetic sequence of the unknown virus from infected chimpanzee blood, identifying it as a new RNA virus of the Flavivirus family, which they named Hepatitis C virus.

Charles M. Rice

Charles M. Rice was born on 25 August 1952 in Sacramento, CA, USA. At the time of the award he was affiliated with the Rockefeller University, New York, NY, USA, and he received one third of the prize.

Rice engineered a genetic variant of Hepatitis C virus and showed, by injecting it into chimpanzees, that this virus alone was sufficient to cause the disease, supplying the final proof of causation.

What problem were the laureates trying to solve?

Hepatitis means inflammation of the liver, and by the 1940s doctors had recognised two broad types of infectious hepatitis. One type, later called hepatitis A, spread through contaminated water or food and generally caused only short-term illness.

The other type spread through blood and bodily fluids and was far more dangerous because it could become chronic, silently damaging the liver for years before causing cirrhosis (scarring) or liver cancer.

The scientific background notes that before the 1960s, up to 30% of patients who had surgery or multiple blood transfusions risked developing this chronic form.

In the 1960s, Baruch Blumberg identified the agent behind one blood-borne form, the Hepatitis B virus, work for which he won the Nobel Prize in Physiology or Medicine in 1976. Blumberg's discovery allowed blood banks to screen out infected donors and led to the first vaccine against the virus.

Blood tests that screened out Hepatitis B reduced transfusion-related hepatitis, but excluding Hepatitis B antibody-positive donors prevented only around 20% of post-transfusion hepatitis cases.

Harvey Alter and his colleagues at the NIH found that the remaining, larger share of cases stayed unexplained even after excluding both Hepatitis A and Hepatitis B. This mystery illness was given the placeholder name "non-A, non-B" hepatitis.

The scale of the problem was serious: blood-borne hepatitis, the press release noted, causes more than a million deaths a year worldwide, a burden the press release compared to that of HIV infection and tuberculosis.

The scientific background adds that, according to the World Health Organization's Global Hepatitis Report, 257 million people were living with chronic Hepatitis B and 72 million with chronic Hepatitis C in the year of that report, with 1.34 million deaths in 2015, a 63% rise since 1990, mainly due to Hepatitis C.

Finding the hidden agent responsible for the unexplained cases became a pressing goal of virology, but the traditional tools used to hunt viruses failed to find it for over a decade.

How did Alter prove an unknown virus was involved?

Alter's contribution was methodical clinical detective work rather than a single experiment. As a young doctor he had already worked with Baruch Blumberg on the discovery of the antigen that revealed Hepatitis B virus, and he carried that careful, patient-by-patient approach into his own research at the NIH Blood Bank.

By carefully tracking patients who had received blood transfusions, his team showed that a form of chronic hepatitis persisted even when known viral causes were ruled out.

1. Collect blood samples from transfusion patients who developed hepatitis of unknown cause.
2. Test these samples for Hepatitis A and Hepatitis B antibodies and exclude both as the cause.
3. Transfer the mystery-hepatitis blood into chimpanzees, the only non-human species known to be susceptible.
4. Observe that the chimpanzees developed hepatitis, proving the disease was transmissible by an infectious agent.
5. Show, through further tests, that the agent had the general characteristics of a virus, defining "non-A, non-B" hepatitis as a distinct disease.

This chimpanzee transmission work, reported formally in 1978, was crucial: it proved an infectious agent existed even though nobody could yet see or name it, and it gave later researchers a living system in which to test any candidate virus.

Alter and his co-workers went further still, using treatments on infected plasma to show that the unknown agent contained essential lipids, a feature shared by all enveloped viruses, and estimating that it measured roughly 30 to 60 nanometres across.

These physical clues narrowed down what kind of virus the molecular hunters should expect to find.

How did Houghton isolate the virus itself?

Michael Houghton, working at the Chiron Corporation, began his molecular hunt for the mystery agent in 1982. His team built a collection, or library, of DNA fragments copied from genetic material found in the blood of an infected chimpanzee.

1. Extract nucleic acids from the blood of a chimpanzee infected with the mystery agent.
2. Make a large collection of cloned DNA fragments from this material, most of which came from the chimpanzee's own genome.
3. Use blood serum from hepatitis patients, reasoning that it would contain antibodies against the unknown virus, to screen the DNA fragments for ones producing a matching viral protein.
4. After an extensive search through roughly one million bacterial colonies, identify a single positive clone that reacted with patient antibodies.
5. Determine that this clone, named clone 5-1-1, came from a novel RNA virus of the Flavivirus family, and name it Hepatitis C virus.

Earlier attempts using only the chimpanzee's own genetic material, without the antibody-screening step, had identified nothing but host genes, so Houghton's team, working with Qui-Lim Choo and George Kuo, had to try this untested immune-screening strategy before it finally succeeded.

The presence of matching antibodies in many chronic hepatitis patients, including a donor who had passed the disease to ten separate recipients, strongly suggested that this newly cloned virus was the long-sought cause.

This approach, screening with patient antibodies rather than looking for the virus directly, succeeded where more traditional virus-hunting methods had failed for over ten years.

A student should draw three linked boxes in sequence: the first labelled "Alter: transfusion patients develop hepatitis, agent transmits to chimpanzees"; the second labelled "Houghton: viral DNA clone isolated from infected chimpanzee blood, named Hepatitis C virus"; the third labelled "Rice: engineered virus alone causes hepatitis in chimpanzees", with an arrow running left to right showing the build-up of proof.

How did Rice provide the final proof?

Finding and naming a virus is not the same as proving it causes a disease on its own; other factors might still be needed. Charles M. Rice, working at Washington University in St Louis, set out to answer this directly.

Rice, alongside a separate group led by Kunitada Shimotohno in Tokyo studying the same question, noticed an uncharacterised region at one end of the Hepatitis C virus genome that they suspected mattered for the virus to copy itself.

He also noticed that some isolated copies of the virus carried genetic changes that might stop it from replicating properly.

This experiment, published in 1997, was the final proof that Hepatitis C virus alone, with no other agent needed, could cause the disease that had puzzled doctors since the 1970s. A separately engineered viral genome built by another laboratory soon confirmed the same result.

How did the discovery unfold?

Why does this discovery matter?

Once Hepatitis C virus had been identified and proven to cause disease, scientists could develop highly sensitive blood tests for it.

According to the press release, these tests have "essentially eliminated post-transfusion hepatitis in many parts of the world," a major improvement in global health for anyone needing blood transfusions or blood products.

The discovery also enabled the rapid development of antiviral drugs that directly target the virus. For the first time in history, the press release states, the disease can now be cured, and this raises hopes of eventually eliminating Hepatitis C virus from the human population.

Open challenges remain. The scientific background notes that, according to a WHO Global Hepatitis Report, fewer than 20% of people with Hepatitis B or Hepatitis C infection had been adequately diagnosed worldwide, and the cost of the most effective treatments remains high in many places.

Achieving worldwide elimination will therefore require international efforts to extend blood testing and to make antiviral drugs available across the globe.

How does this connect to what you study?

This discovery connects directly to biology topics taught in school science. It touches the structure and function of the liver, the organ damaged in hepatitis, and shows what happens when an organ is attacked over long periods: the scientific background notes that chronic infection can progress to cirrhosis, permanent scarring, and even liver cancer.

It also illustrates how viruses work as infectious agents carrying genetic material, in this case RNA rather than DNA, and how this material can be copied, studied and even artificially engineered in a laboratory, as Rice did when building a working copy of the Hepatitis C virus genome.

The story demonstrates how the immune system responds to infection by producing antibodies, and how scientists cleverly used patient antibodies, rather than looking for the virus directly, to find the genetic clone that proved to be the missing agent.

It also shows how animal models, here chimpanzees, were historically used in medical research to test whether an agent alone could cause a disease, a step beyond merely observing an association.

Finally, it is a clear example of the scientific method: careful observation of patients over years, forming a hypothesis about an unseen cause, and testing that hypothesis through repeated, independent experiments by different researchers across decades, each building on the last.

What antiviral treatments became possible after the discovery?

Identifying Hepatitis C virus opened the door to testing medicines directly against it, but early treatments were disappointing. The scientific background notes that recombinant interferon and the drug ribavirin, used in the earliest regimens, were often ineffective and came with significant side effects.

Progress came gradually. A modified, longer-acting form called pegylated interferon improved results at the end of the 1990s, and researchers then began developing drugs that targeted specific viral proteins directly, rather than boosting the immune system in general.

1. Protease inhibitors such as boceprevir, telaprevir and simeprevir were introduced to block an enzyme the virus needs to mature.
2. Drugs such as sofosbuvir were designed to block the viral enzyme that copies the virus's RNA genome.
3. Drugs such as ledipasvir were designed to block a separate viral protein needed for the virus to replicate.
4. These drugs were combined into regimens called directly acting antivirals (DAAs), which target several viral functions at once.

According to the scientific background, short courses of these combined antiviral treatments now cure more than 95% of patients, including many advanced cases that had not responded to earlier treatments, with only minor side effects and a much lower risk of the virus developing drug resistance.

Laboratory tools built on the laureates' work made this possible: researchers at the University of Heidelberg built virus fragments that could replicate efficiently in liver cancer cell lines, and others later produced small animal models by grafting human liver cells into immune-deficient mice, giving scientists practical systems in which to test candidate drugs before they reached patients.

Quick facts for exams

The Nobel Prize in Physiology or Medicine 2020 was awarded jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice "for the discovery of Hepatitis C virus".

The award was announced on 5 October 2020 by the Nobel Assembly at Karolinska Institutet, which awards the Nobel Prize in Physiology or Medicine; its Nobel Committee evaluates the nominations.

Alter worked at the US National Institutes of Health and proved an unknown virus caused chronic post-transfusion hepatitis;

Houghton, at Chiron Corporation (later University of Alberta), isolated the virus's genome; and Rice, at Washington University in St Louis (later Rockefeller University), proved the virus alone could cause the disease. Each laureate received one third of the prize.

Note: Source. The prize facts in this note are from the Nobel Prize's official site, nobelprize.org.

Glossary

• Hepatitis — inflammation of the liver, which can be caused by viruses, toxins, alcohol or autoimmune disease.
• Chronic hepatitis — long-lasting liver inflammation that can progress over years to cirrhosis or liver cancer.
• Cirrhosis — permanent scarring of the liver that damages its ability to function.
• Hepatitis A virus — a virus spread by contaminated food or water, usually causing short-term illness.
• Hepatitis B virus — a blood-borne virus discovered by Baruch Blumberg, who won the 1976 Nobel Prize for identifying it.
• Hepatitis C virus — the RNA virus of the Flavivirus family, identified in 1989, that causes most of the remaining blood-borne chronic hepatitis cases.
• "Non-A, non-B" hepatitis — the working name given to the unexplained form of transfusion-related chronic hepatitis before its viral cause was found.
• RNA virus — a virus whose genetic material is ribonucleic acid rather than DNA.
• Flavivirus family — a group of RNA viruses to which Hepatitis C virus was shown to belong.
• Genome — the complete set of genetic material of an organism or virus.
• Antibody — a protein made by the immune system that recognises and binds to a specific foreign substance, such as a viral protein.
• Clone (molecular biology) — a copied fragment of genetic material produced for study, used by Houghton's team to isolate the virus.
• Transfusion — the transfer of blood or blood products from a donor to a patient, historically a route for spreading blood-borne hepatitis.

Common errors and misconceptions

• Misconception: Hepatitis C virus was discovered by one scientist alone. Correct: The discovery built on decades of work by Alter (clinical proof of an unknown agent), Houghton (genome isolation) and Rice (final proof of causation).
• Misconception: Hepatitis A and Hepatitis C are the same type of disease. Correct: Hepatitis A spreads through contaminated food or water and is usually short-lived, while Hepatitis C is blood-borne and can become chronic.
• Misconception: The virus was identified by looking at it under a microscope. Correct: It was identified through molecular cloning of genetic material and screening with patient antibodies, not by direct visual observation.
• Misconception: Baruch Blumberg discovered Hepatitis C virus. Correct: Blumberg discovered Hepatitis B virus in the 1960s and won the 1976 Nobel Prize; Hepatitis C was identified later, in 1989, by Houghton's team.
• Misconception: Hepatitis C has no cure. Correct: According to the press release, antiviral drugs developed after the virus's discovery can now cure the disease in most treated patients.
• Misconception: The 2020 Medicine prize was for a COVID-19 discovery. Correct: The citation was specifically "for the discovery of Hepatitis C virus", a separate, decades-long body of work.

Exam-style questions with model answers

Q1. For what citation was the 2020 Nobel Prize in Physiology or Medicine awarded? [2 marks]

1. It was awarded "for the discovery of Hepatitis C virus", jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice.

Q2. Name the three 2020 Medicine laureates and their affiliations at the time of the award. [2 marks]

1. Harvey J. Alter was at the National Institutes of Health, USA; Michael Houghton was at the University of Alberta, Canada; Charles M. Rice was at Rockefeller University, USA.

Q3. Explain how Harvey Alter proved that an unknown infectious agent caused some cases of post-transfusion hepatitis. [4 marks]

1. Alter studied patients who developed chronic hepatitis after blood transfusions, even when tests for Hepatitis A and Hepatitis B were negative.
2. He and his colleagues showed that blood from these patients could transmit the disease to chimpanzees, the only susceptible non-human host.
3. Further tests showed the transmissible agent had the properties of a virus, rather than a toxin or other non-living cause.
4. This defined a distinct, unexplained form of chronic viral hepatitis, then named "non-A, non-B" hepatitis.

Q4. Describe how Michael Houghton's team isolated the genome of Hepatitis C virus. [4 marks]

1. Houghton's team, working at Chiron Corporation, built a library of cloned DNA fragments from nucleic acids in the blood of an infected chimpanzee.
2. Most fragments came from the chimpanzee's own genome, so the team needed a way to pick out the few viral ones.
3. They used serum from hepatitis patients, assumed to contain antibodies against the unknown virus, to screen the DNA fragments for one producing a matching viral protein.
4. After an extensive search, a single positive clone was found, which was shown to come from a new RNA virus of the Flavivirus family, named Hepatitis C virus.

Q5. Discuss how the three laureates' work together established that Hepatitis C virus alone causes hepatitis, and explain why this discovery matters for public health today. [6 marks]

1. Alter's studies first showed that an unknown, transmissible agent was responsible for many unexplained cases of chronic post-transfusion hepatitis, by transferring infected blood to chimpanzees.
2. Houghton's team then isolated the genetic material of this agent, identifying it as a new RNA virus of the Flavivirus family and naming it Hepatitis C virus, with matching antibodies found in many hepatitis patients.
3. However, this still did not prove the virus alone was sufficient to cause disease, since other factors in infected blood could not be ruled out.
4. Charles Rice resolved this by engineering a complete viral genome, free of inactivating mutations and containing an important genome region needed for replication, then injecting it into chimpanzees.
5. The chimpanzees developed virus in their blood and liver damage resembling human chronic hepatitis, giving the final proof that Hepatitis C virus alone caused the disease.
6. This combined proof allowed the development of sensitive blood tests, which the press release says "have essentially eliminated post-transfusion hepatitis in many parts of the world," and of antiviral drugs that can now cure the disease, raising hopes of eventually eliminating the virus worldwide, though broader access to testing and treatment is still needed.

Q6. What was the role of chimpanzees in proving the existence and effects of Hepatitis C virus? [3 marks]

1. Chimpanzees were the only known non-human species susceptible to infection by the unknown hepatitis agent.
2. Alter used them to prove the mystery agent was transmissible and virus-like, before it had a name.
3. Rice later used them to prove that an engineered copy of Hepatitis C virus alone could reproduce the disease, giving the final proof of causation.

Q7. Why could blood tests developed after this discovery reduce the spread of Hepatitis C? [3 marks]

1. Once the virus's genome and proteins were known, sensitive tests could detect antibodies or viral material in donated blood.
2. Infected blood or blood products could then be identified and excluded from transfusions.
3. The press release states that these tests have "essentially eliminated post-transfusion hepatitis in many parts of the world."

Q8. State one earlier Nobel Prize connected to hepatitis research mentioned alongside this discovery. [1 mark]

1. Baruch Blumberg won the 1976 Nobel Prize in Physiology or Medicine for discovering the Hepatitis B virus.

Key takeaways

• The 2020 Medicine Nobel went jointly to Alter, Houghton and Rice for discovering Hepatitis C virus.
• Alter proved an unknown, virus-like agent caused many unexplained cases of chronic post-transfusion hepatitis.
• Houghton's team isolated the viral genome in 1989 using patient-antibody screening of cloned DNA fragments.
• Rice supplied the final proof in 1997 by showing an engineered viral genome alone caused hepatitis in chimpanzees.
• Hepatitis C virus is an RNA virus belonging to the Flavivirus family.
• The discovery enabled sensitive blood tests that have essentially eliminated post-transfusion hepatitis in many regions.
• It also enabled antiviral drugs that can now cure the disease, a historic first according to the press release.
• Wider access to blood screening and treatment worldwide remains a goal still to be achieved.

Test yourself

What citation did the 2020 Nobel Prize in Physiology or Medicine carry?

It was awarded "for the discovery of Hepatitis C virus", jointly to Alter, Houghton and Rice.

Where was Harvey J. Alter affiliated at the time of the award?

Harvey J. Alter was affiliated with the National Institutes of Health in Bethesda, MD, USA.

What family of viruses does Hepatitis C virus belong to?

Hepatitis C virus was shown to be a novel RNA virus belonging to the Flavivirus family.

What animal model let researchers test whether the mystery agent was infectious?

Chimpanzees were the only non-human species shown to be susceptible, allowing transmission experiments.

What did Rice's 1997 experiment finally prove?

It proved that an engineered Hepatitis C virus genome alone, without other factors, could cause hepatitis in chimpanzees.

What earlier hepatitis virus discovery won a Nobel Prize in 1976?

Baruch Blumberg's discovery of the Hepatitis B virus won him the 1976 Nobel Prize in Physiology or Medicine.

What practical medical benefit followed from identifying Hepatitis C virus?

It allowed sensitive blood tests and effective antiviral drugs that have reduced transfusion-related infection and can cure the disease.